Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Seven RNAi-Related Patent Applications: Feb 1, 2007

Premium
Title: Modulation of HIF1-Alpha and HIF2-Alpha Expression
 
Number: 20070020679
 
Filed: Sept. 26, 2006
 
Lead Inventor: Donna Ward, Isis Pharmaceuticals
 
According to the patent application’s abstract, the invention comprises “compounds, compositions, and methods … for modulating the expression of HIF1-alpha and/or HIF2-alpha. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1-alpha and HIF2-alpha. Methods of using these compounds for modulation of HIF1-alpha and/or HIF2-alpha expression and for diagnosis and treatment of disease associated with expression of HIF1-alpha and/or HIF2-alpha” are also covered, the abstract notes.
 

 
Title: Solid Surface for Biomolecule Delivery and High-Throughput Assay
 
Number: 20070020761
 
Filed: Sept. 26, 2006
 
Lead Inventor: Lei Yu, Nitto Denko
 
The invention, the patent application’s abstract states, “is related to a method for introducing biomolecules, such as nucleic acids, into cells by culturing cells on a solid surface, which is coated with transfection reagents and biomolecules.”
 

 
Title: Modulation of Endothelial Lipase Expression
 
Number: 20070020675
 
Filed: Aug. 9, 2006
 
Inventor: Kenneth Dobie, Isis Pharmaceuticals
 
The patent application, its abstract states, claims “compounds, compositions, and methods … for modulating the expression of endothelial lipase. The compositions comprise oligonucleotides, targeted to nucleic acid encoding endothelial lipase. Methods of using these compounds for modulation of endothelial lipase expression and for diagnosis and treatment of disease associated with expression of endothelial lipase” are also covered by the application.
 

 
Title: Methods and Composition for RNA Interference
 
Number: 20070020652
 
Filed: April 28, 2006
 
Lead Inventor: Alvarado Sanchez, University of Utah
 
“The invention relates to improved methods of attenuating expression of a target gene in a eukaryotic cell with dsRNA, identifying nucleic acid sequences responsible for conferring a particular phenotype to a cell, alleviating pest infestation in plants, and altering gene expression in an undifferentiated stem cell or the differentiated progeny thereof,” the patent application’s abstract states. “Transcription of the RNA, which will form the dsRNA, is terminated by one or more terminators sequences, thereby increasing the efficiency of inhibition.”
 

 
Title: Methods and Reagents for Treatment and Diagnosis of Age-Related Macular Degeneration
 
Number: 20070020647
 
Filed: Feb. 14, 2006
 
Lead Inventor: Gregory Hageman, University of Iowa
 
“The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD,” the patent application’s abstract states. “The invention provides methods and reagents for diagnosis and treatment of AMD.”
Specifically, the application claims the use of antisense and RNAi molecules to reduce expression of Factor H protein.
 

 
Title: Method for Detection and Characterization of Short Nucleic Acids
 
Number: 20070020644
 
Filed: Jan. 26, 2006
 
Lead Inventor: Alexander Kolykhalov, Benitec
 
The patent application, its abstract states, covers “a method of detecting and characterizing a target short RNA.”
 

 
Title: Method of Targeted Gene Delivery Using Viral Vectors
 
Number: 20070020238
 
Filed: June 1, 2006
 
Lead Inventor: David Baltimore, California Institute of Technology
 
According to its abstract, the patent application covers “methods and compositions … for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic molecule is also present on the envelope and facilitates delivery of the polynucleotide across the membrane and into the cytosol of the target cell,” the abstract states. “The methods and related compositions can be used for treating patients having suffering from a wide range of conditions, including infection, such as HIV; cancers, such as non-Hodgkin's lymphoma and breast cancer; and hematological disorders, such as severe combined immunodeficiency.”

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.